Chief Financial Officer
United States of America
Chuck has more than 30 years of financial experience in life sciences as both a public and private company Chief Financial Officer, as well as a partner with Coopers & Lybrand (a predecessor firm to PricewaterhouseCoopers). Chuck has raised $1.0 billion to finance pioneering products for public companies and venture backed startups. His experience ranges from developmental R&D stage companies to commercial companies generating international revenues of over $350 million. He has led or played significant roles in IPOs, mergers, acquisitions, divestments, corporate alliances, licensing arrangements, corporate and debt restructurings, operational turnarounds and building investor relations programs. Chuck is currently Managing Director of CFGI’s Life Sciences Financial Consulting practice and over his career has held CFO positions with Coley Pharmaceutical Group, BG Medicine, Knome, Molecular Insight and W. R. Grace Health Care. As CFO of Coley, Chuck worked alongside Art, Bob and Chuck Yon, and played key roles in Coley’s IPO and sale to Pfizer. Chuck received a B.S. in Business Administration from Norwich University and a M.B.A. from the Wharton School of the University of Pennsylvania.